Anti-vascular endothelial growth factor (VEGF) agents for limiting the function of VEGF are considered as recommended standard treatments for wet AMD, while several intravitreal complement inhibitors that target complement component 3 (C3) and complement component 5 (C5) offer a potential therapeutic option for dry AMD [21,22]. The gene discussed is VEGFA; the disease is wet macular degeneration.